Reviva Pharmaceuticals Holdings (RVPH) Stock Statistics & Valuation Metrics

Reviva Pharmaceuticals Holdings has a market cap or net worth of $4.59M. The enterprise value is -$11.44M.

Market Cap

$4.59M

Enterprise Value

-$11.44M

Reviva Pharmaceuticals Holdings has 13,110,377 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

13,110,377

Owned by Insiders

16.02%

Owned by Institutions

0.01%

Reviva Pharmaceuticals Holdings’s return on equity (ROE) is -2.30 and return on invested capital (ROIC) is -223.09%.

Return on Equity (ROE)

-2.30

Return on Assets (ROA)

-1.25

Return on Invested Capital (ROIC)

-223.09%

Return on Capital Employed (ROCE)

-2.34

Revenue Per Employee

0

Profits Per Employee

-1.42M

Employee Count

14

Asset Turnover

0.00

Inventory Turnover

0.00

The current PE Ratio of Reviva Pharmaceuticals Holdings is -0.05. Reviva Pharmaceuticals Holdings’s PEG ratio is -0.00.

PE Ratio

-0.05

PS Ratio

0.00

PB Ratio

0.00

Price to FCF

-0.00

Price to Operating Cash Flow

-0.00

PEG Ratio

-0.00

In the last 12 months, Reviva Pharmaceuticals Holdings had revenue of 0 and earned -19.86M in profits. Earnings per share was -5.48.

Revenue

0

Gross Profit

0

Operating Income

-20.20M

Pretax Income

-19.85M

Net Income

-19.86M

EBITDA

-19.83M

Earnings Per Share (EPS)

-5.48

In the last 12 months, operating cash flow was -5.92T and capital expenditures 0, giving a free cash flow of -5.92T billion.

Operating Cash Flow

-5.92T

Free Cash Flow

-5.92T

Free Cash Flow per Share

-447930.15

Reviva Pharmaceuticals Holdings pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share

―

Dividend Yield

―

Payout Ratio

N/A

Free Cash Flow Yield

-128942773.97%

Earnings Yield

-52947483.31%

Beta

1.60

52-Week Price Change

-97.10%

50-Day Moving Average

0.49

200-Day Moving Average

1.41

Relative Strength Index (RSI)

31.36

Average Volume (3m)

29.16K

Reviva Pharmaceuticals Holdings upcoming earnings date is Nov 16, 2026, TBA (Not Confirmed).

Last Earnings Date

Aug 12, 2026

Next Earnings Date

Nov 16, 2026

Ex-Dividend Date

―

Reviva Pharmaceuticals Holdings as a current ratio of 2.08, with Debt / Equity ratio of 4.71%

Current Ratio

2.08

Quick Ratio

2.08

Debt to Market Cap

0.02

Net Debt to EBITDA

0.71

Interest Coverage Ratio

-1507.24

In the past 12 months, Reviva Pharmaceuticals Holdings has paid 18.89K in taxes.

Income Tax

18.89K

Effective Tax Rate

-0.00

Reviva Pharmaceuticals Holdings EV to EBITDA ratio is 7.54, with an EV/FCF ratio of 3.34.

EV to Sales

0.00

EV to EBITDA

7.54

EV to Free Cash Flow

3.34

EV to Operating Cash Flow

3.34

Reviva Pharmaceuticals Holdings has $19.89T in cash and marketable securities with $144.09B in debt, giving a net cash position of $19.75T billion.

Cash & Marketable Securities

$19.89T

Total Debt

$144.09B

Net Cash

$19.75T

Net Cash Per Share

$1.51M

Tangible Book Value Per Share

$1.15M

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

Gross Margin

0.00%

Operating Margin

0.00%

Pretax Margin

0.00%

Net Profit Margin

0.00%

EBITDA Margin

0.00%

EBIT Margin

0.00%

The average price target for Reviva Pharmaceuticals Holdings is ―, which is 11.43% higher than the current price. The consensus rating is ―

Price Target

―

Price Target Upside

―

Analyst Consensus

―

Analyst Count

―

Revenue Growth Forecast

―

EPS Growth Forecast

82.20%

Smart Score

―

AI Score

41